Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations

There are multiple drugs for the treatment of type 2 diabetes, including traditional sulfonylureas biguanides, glinides, thiazolidinediones, α-glucosidase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SG...

Full description

Bibliographic Details
Main Authors: Shitao Zhang, Yi Wang, Lu Han, Xueqi Fu, Song Wang, Wannan Li, Weiwei Han
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Chemistry
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fchem.2021.711242/full
id doaj-fb38f10f612d4c87a0063fb5bfebe1aa
record_format Article
spelling doaj-fb38f10f612d4c87a0063fb5bfebe1aa2021-09-03T14:44:44ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462021-08-01910.3389/fchem.2021.711242711242Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics SimulationsShitao Zhang0Yi Wang1Lu Han2Xueqi Fu3Song Wang4Wannan Li5Weiwei Han6School of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaSchool of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaSchool of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaSchool of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaLaboratory of Theoretical and Computational Chemistry, Institute of Theoretical Chemistry, Jilin University, Changchun, ChinaSchool of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaSchool of Life Science, Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, National Engineering Laboratory for AIDS Vaccine, Jilin University, Changchun, ChinaThere are multiple drugs for the treatment of type 2 diabetes, including traditional sulfonylureas biguanides, glinides, thiazolidinediones, α-glucosidase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. α-Glucosidase inhibitors have been used to control postprandial glucose levels caused by type 2 diabetes since 1990. α-Glucosidases are rather crucial in the human metabolic system and are principally found in families 13 and 31. Maltase-glucoamylase (MGAM) belongs to glycoside hydrolase family 31. The main function of MGAM is to digest terminal starch products left after the enzymatic action of α-amylase; hence, MGAM becomes an efficient drug target for insulin resistance. In order to explore the conformational changes in the active pocket and unbinding pathway for NtMGAM, molecular dynamics (MD) simulations and adaptive steered molecular dynamics (ASMD) simulations were performed for two NtMGAM-inhibitor [de-O-sulfonated kotalanol (DSK) and acarbose] complexes. MD simulations indicated that DSK bound to NtMGAM may influence two domains (inserted loop 1 and inserted loop 2) by interfering with the spiralization of residue 497–499. The flexibility of inserted loop 1 and inserted loop 2 can influence the volume of the active pocket of NtMGAM, which can affect the binding progress for DSK to NtMGAM. ASMD simulations showed that compared to acarbose, DSK escaped from NtMGAM easily with lower energy. Asp542 is an important residue on the bottleneck of the active pocket of NtMGAM and could generate hydrogen bonds with DSK continuously. Our theoretical results may provide some useful clues for designing new α-glucosidase inhibitors to treat type 2 diabetes.https://www.frontiersin.org/articles/10.3389/fchem.2021.711242/fullmaltase-glucoamylaseinhibitorsmolecular dynamics simulationsadaptive steered molecular dynamics simulationsconformational change
collection DOAJ
language English
format Article
sources DOAJ
author Shitao Zhang
Yi Wang
Lu Han
Xueqi Fu
Song Wang
Wannan Li
Weiwei Han
spellingShingle Shitao Zhang
Yi Wang
Lu Han
Xueqi Fu
Song Wang
Wannan Li
Weiwei Han
Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
Frontiers in Chemistry
maltase-glucoamylase
inhibitors
molecular dynamics simulations
adaptive steered molecular dynamics simulations
conformational change
author_facet Shitao Zhang
Yi Wang
Lu Han
Xueqi Fu
Song Wang
Wannan Li
Weiwei Han
author_sort Shitao Zhang
title Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
title_short Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
title_full Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
title_fullStr Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
title_full_unstemmed Targeting N-Terminal Human Maltase-Glucoamylase to Unravel Possible Inhibitors Using Molecular Docking, Molecular Dynamics Simulations, and Adaptive Steered Molecular Dynamics Simulations
title_sort targeting n-terminal human maltase-glucoamylase to unravel possible inhibitors using molecular docking, molecular dynamics simulations, and adaptive steered molecular dynamics simulations
publisher Frontiers Media S.A.
series Frontiers in Chemistry
issn 2296-2646
publishDate 2021-08-01
description There are multiple drugs for the treatment of type 2 diabetes, including traditional sulfonylureas biguanides, glinides, thiazolidinediones, α-glucosidase inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase IV (DPP-4) inhibitors, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. α-Glucosidase inhibitors have been used to control postprandial glucose levels caused by type 2 diabetes since 1990. α-Glucosidases are rather crucial in the human metabolic system and are principally found in families 13 and 31. Maltase-glucoamylase (MGAM) belongs to glycoside hydrolase family 31. The main function of MGAM is to digest terminal starch products left after the enzymatic action of α-amylase; hence, MGAM becomes an efficient drug target for insulin resistance. In order to explore the conformational changes in the active pocket and unbinding pathway for NtMGAM, molecular dynamics (MD) simulations and adaptive steered molecular dynamics (ASMD) simulations were performed for two NtMGAM-inhibitor [de-O-sulfonated kotalanol (DSK) and acarbose] complexes. MD simulations indicated that DSK bound to NtMGAM may influence two domains (inserted loop 1 and inserted loop 2) by interfering with the spiralization of residue 497–499. The flexibility of inserted loop 1 and inserted loop 2 can influence the volume of the active pocket of NtMGAM, which can affect the binding progress for DSK to NtMGAM. ASMD simulations showed that compared to acarbose, DSK escaped from NtMGAM easily with lower energy. Asp542 is an important residue on the bottleneck of the active pocket of NtMGAM and could generate hydrogen bonds with DSK continuously. Our theoretical results may provide some useful clues for designing new α-glucosidase inhibitors to treat type 2 diabetes.
topic maltase-glucoamylase
inhibitors
molecular dynamics simulations
adaptive steered molecular dynamics simulations
conformational change
url https://www.frontiersin.org/articles/10.3389/fchem.2021.711242/full
work_keys_str_mv AT shitaozhang targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT yiwang targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT luhan targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT xueqifu targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT songwang targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT wannanli targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
AT weiweihan targetingnterminalhumanmaltaseglucoamylasetounravelpossibleinhibitorsusingmoleculardockingmoleculardynamicssimulationsandadaptivesteeredmoleculardynamicssimulations
_version_ 1717816287443288064